You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Carbon nanomaterials as contrast agents for breast cancer diagnosis and therapy
Free
  1. Sara Dolci1,
  2. Valentina Domenici1,
  3. Gianpaolo Vidili2,
  4. Elisabetta Avitabile2,
  5. Marco Orecchioni2,
  6. Alberto Bianco3 and
  7. Lucia Delogu2
  1. Aff1 grid.5395.a0000000417573729University of Pisa Pisa Italy
  2. Aff2 grid.11450.310000000120979138University of Sassari Sassari Italy
  3. Aff3 grid.465534.50000 0004 0638 0833CNRS, Institut de Biologie Moléculaire et CellulaireLaboratoire d’Immunologie et Chimie Thérapeutiques Strasbourg France

https://doi.org/10.1186/2051-1426-3-S1-P5

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Nanotechnology is the promise to fight breast cancer (BC) more specifically and effectively [1]. In this context carbon nanomaterials (CNs) have attracted the scientific community and the public interest [2]. Common modalities for BC diagnosis are ultrasonography (US) and magnetic resonance imaging (MRI). US is the most useful modality in the evaluation of palpable BC masses that are mammographically occult in women younger than 30’s. Here we show CNs as highly and long lasting echogenic materials. Experiments on swine models confirmed that CNs are clearly visible under US and didn’t exert toxicity. In the current market dual-imaging agents are missed; here we also demonstrate the immune-compatibility and high echogenic properties in water and in whole blood of cysteine functionalized super paramagnetic nanoparticles (CY-SPION), well-known MRI agents [3]. Thanks to these findings, and the ability to load CNs to many moieties [4–6], we propose dual-contrast agents, CNs-CY-SPION conjugates, to improve BC diagnosis. Future perspectives is to conjugate CN-SPION to targeted drugs against BC. In summary, we lay the foundations for novel contrast agents, for therapy and multimodal diagnosis of BC, combining high imaging performances with unique potential therapeutic applications, such as specific targeting capabilities, drug delivery, immunotherapy and hyperthermia.

    References

    1. 1.↵
      Avitabile E, Bedognetti D, Sgarella F, Delogu LG: Nanotechnology fight for breast cancer. (under preparation)
    2. 2.↵
      1. Sechi G,
      2. Bedognetti D,
      3. Sgarrella F,
      4. Van Eperen, L,
      5. Marincola FM,
      6. Bianco A,
      7. Delogu LG
      . The perception of nanotechnology and nanomedicine: a worldwide social media study. Nanomedicine. 2014;9:101475–86. doi:10.2217/nnm.14.78
      OpenUrl
    3. 3.↵
      1. Dolci A,
      2. Ierardic V,
      3. Gradi A,
      4. Jagli Z,
      5. Remskard M,
      6. Apihd T,
      7. Cifellia M,
      8. Pampalonia G,
      9. Veracinia CA,
      10. Domenici V
      . Precursors of Magnetic Resonance Imaging Contrast Agents Based on Cystine-coated Iron-oxide Nanoparticles. Current Physical Chemistry. 2013;3:4493–500. doi:10.2174/18779468113036660009
      OpenUrl
    4. 4.↵
      1. Delogu LG,
      2. Magrini A,
      3. Bergamaschi A,
      4. Rosato N,
      5. Dawson MI,
      6. Bottini N
      . Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug Chem. 2009;18:20427–431. doi:10.1021/bc800540j
      OpenUrl
    5. 5.
      1. Delogu LG,
      2. Venturelli E,
      3. Manetti R,
      4. Pinna GA,
      5. Carru C,
      6. Madeddu R,
      7. Murgia L,
      8. Sgarrella F,
      9. Dumortier H,
      10. Bianco A
      . Ex vivo impact of functionalized carbon nanotubes on human immune cells. Nanomedicine (Lond). 2012;7:2231–243. doi:10.2217/nnm.11.101
      OpenUrl
    6. 6.↵
      1. Modugno G,
      2. Ménard-Moyon C,
      3. Prato M,
      4. Bianco A
      . Carbon nanomaterials combined with metal nanoparticles for theranostic applications. Br J Pharmacol. 2015;172:4975–91. doi:10.1111/bph.12984
      OpenUrl